Loading...

Rhythm Pharmaceuticals, Inc.

RYTM•NASDAQ
Healthcare
Biotechnology
$89.27
$24.13(37.04%)

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Overview

Explore Rhythm Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 69.9/100

Key Financials

Market Cap5.7B
P/E Ratio-32.34
EPS (TTM)$-2.80
ROE-1.80%
Fundamental Analysis

AI Price Forecasts

1 Week$64.56
1 Month$69.56
3 Months$67.72
1 Year Target$88.50

RYTM Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Rhythm Pharmaceuticals, Inc. (RYTM) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 57.65, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $88.50.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -32.34 and a market capitalization of 5.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

57.65RSI (14)
0.65MACD
16.11ADX
Revenue Growth
68.06%
↑ 68.06%
Profit Growth
$-2.70
↓ 41.11%
EPS Growth
$-2.70
↓ 31.56%
Operating Margin
-126.13%
↓ 44.02%
ROE
-179.82%
↓ 41.11%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
0
Buy
6
Hold
0
Sell
0
Strong Sell
0

Price Targets

Low$55.00
Average$66.67
High$80.00

Company Profile

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

CEO

David P. Meeker

Employees

283

Headquarters

222 Berkeley Street, Boston, MA

Founded

2017

Frequently Asked Questions

;